Metastasis Research Society

We can’t wait to learn more about Toni’s latest discoveries and insights into metastasis and cancer immunology.
Join us at #MRS2026 in Utah — you won’t want to miss it!
🗓 When: June 28 – July 1, 2026
📍 Where: Salt Lake City, Utah

🌐 Meeting registration is open now!!
👉 tinyurl.com/2zbm7b4b

TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak In metastasis, the dynamics of tumor-immune interactions during micrometastasis remain unclear. Identifying the vulnerabilities of micrometastases bef…

🔬 Moreover, his team recently uncovered how TIM3 upregulation in micrometastasis drives metastatic niche remodeling and enables evasion of immune surveillance.
👇https://www.sciencedirect.com/science/article/pii/S153561082500265X?via%3Dihub

🔬Toni’s group revealed novel functions of LCOR as an immunomodulator mediating the response to ICB. Targeting of LCOR can transform cold ❄️ ER+ breast cancers into hot 🔥 tumors — rendering them sensitive to ICB
👉 www.nature.com/articles/s43...
👉 www.jci.org/articles/vie...

Excited to introduce @tceliaterrassa.bsky.social in our #speakerhighlight 🌟for #MRS2026. Toni is a Group Leader at the Hospital del Mar in beautiful Barcelona & investigates the dynamics of cancer stem cells and the immune microenvironment to understand metastasis & resistance
👉 celiaterrassalab.com

EXCITING NEWS! Registration and abstract submission for the 21st Biennial Congress of the MRS is now OPEN! Find all the information here: metastasis-research.org/2024/06/26/m...

Don't miss her talk!

🗓 When: June 28 – July 1, 2026
📍 Where: Salt Lake City, Utah
👉 Become a member & Save: metastasis-research.org/membership-a...

#MRS2026 #EvanthiaRoussosTorres #BreastCancer #Immunotherapy #TumorMicroenvironment #Metastasis #USC #WomenInScience

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial - Nature Cancer Roussos-Torres and colleagues perform a phase Ib clinical trial of entinostat, nivolumab and ipilimumab in individuals with advanced HER2-negative breast cancer, report on safety and response and char...

🔬By using innovative combinations of mathematical modeling and clinical trials, she is working to "prime" tumors, making them responsive to immunotherapy and giving patients new hope.

🔬 www.nature.com/articles/s43...

🎗️ We are honored to announce that Dr. Evanthia Roussos-Torres @keck.usc.edu will be joining us at #MRS2026!

🔬Dr. Roussos-Torres's lab focuses on the immune TME investigating how metastatic breast cancer cells suppress the immune system to survive in distant organs, such as lung and liver.

See his talk at the meeting!

🗓 June 28 – July 1, 2026
📍 Salt Lake City, Utah
🌐 Meeting registration opens soon!
Save on registration by becoming an MRS member!
👉 metastasis-research.org/membership-a...

#MRS2026 #MasahiroSonoshita #Metastasis #ColorectalCancer #DrugDiscovery #CancerResearch

From dissecting lipid signaling and Notch-driven motility programs in colorectal carcinogenesis to building whole-animal drug-discovery platforms that flag “anti-targets”, his work bridges fundamental biology and translational therapeutics.
👉 bmoncology.wixsite.com/mysite/english

🔬 Prof. Sonoshita leads the Division of Biomedical Oncology at the Institute for Genetic Medicine, Hokkaido University.

His team combines genetics, biochemistry, molecular & cell biology, and medicinal chemistry to uncover mechanisms that drive tumor progression and metastasis.

Counting down to #MRS2026 with our next featured speaker, Prof. Masahiro Sonoshita, PhD.

🗓 June 28 – July 1, 2026
📍 Salt Lake City, Utah
Save on registration by becoming an MRS member!
👉 metastasis-research.org/membership-a...

🎉Stay tuned for open registration and more speaker spotlights!

By revealing these molecular programs, his team aims to identify targetable vulnerabilities to stop metastatic progression.

www.nature.com/articles/s41...

🔬 Dr. Roger Gomis is a Group Leader at the Institute for Research in Biomedicine, Barcelona @irbbarcelona.org. His work aims to unveil how signaling pathways, and gene expression programs control normal cell behavior and cancer cell metastasis, through multi-omics and preclinical cancer modeling.

Countdown to hashtag #MRS2026 continues with our next featured speaker in the #MRS2026 series, Dr. Roger Gomis.

We're looking forward to learning more about his latest discoveries at the meeting.

🗓 June 28 – July 1, 2026
📍 Salt Lake City, Utah
🌐 Meeting registration opens soon! Save on registration by becoming an MRS member!
👉https://metastasis-research.org/membership-account/membership-levels/

A single-cell and spatially resolved atlas of human breast cancers - Nature Genetics A multi-omic atlas of breast cancers, integrating single-cell RNA sequencing, spatial transcriptomics and immunophenotyping, identifies nine ecotypes associated with cellular heterogeneity and prognos...

His lab uses single‑cell genomics and spatial omics to map the cellular ecosystems of breast and prostate cancer, with a particular focus on stromal–epithelial interactions.

www.nature.com/articles/s41...

🔬 We’re pleased to feature Prof. Alexander Swarbrick @alexswarbrick.bsky.social of the Garvan Institute, Australia. His lab uses single‑cell genomics and spatial omics to map the cellular ecosystems of breast and prostate cancer, with a particular focus on stromal–epithelial interactions.

Countdown to #MRS2026! As we continue the countdown to the Biennial Congress in Salt Lake City, we’re excited to highlight another researcher shaping the future of metastasis science.

From amoeboid migration to Rho GTPase signaling, her work reveals how cells reshape their microenvironment to drive metastasis.

🗓 June 28–July 1, 2026
📍 Salt Lake City, Utah
👉 Join the MRS community & save: metastasis-research.org/membership-a...

SLC7A11 protects amoeboid-disseminating cancer cells from oxidative stress Graziani et al. show that SLC7A11 increases during melanoma disease progression. SLC7A11 promotes Myosin II-driven amoeboid invasive behavior while shielding amoeboid cancer cells from oxidative stres...

We’re excited to welcome Prof. Sanz‑Moreno (ICR London), a leader in cytoskeletal dynamics and cancer cell dissemination. Her lab uses cell biology and OMICS to uncover how cancer cells remodel their cytoskeleton to survive, migrate, and invade.

👉 www.cell.com/cell-reports...

Countdown to #MRS2026! How do cancer cells move? Spotlight on Prof. Vicky Sanz‑Moreno 🔬

🗓 June 28–July 1, 2026
📍 Salt Lake City, Utah
👉 Save on registration—become an MRS member: metastasis-research.org/membership-a...

His team is mapping the molecular signals behind this process to develop new immunotherapies that can prevent metastatic disease. Don’t miss his insights on the intersection of genetics, molecular signaling, and tumor immunology at #MRS2026.

A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response - PubMed We present an integrated single-cell RNA sequencing atlas of the primary breast tumor microenvironment (TME) containing 236,363 cells from 119 biopsy samples across eight datasets. In this study, we leverage this resource for multiple analyses of immune and cancer epithelial cell heterogeneity. We d …

🔬 Dr. Chan’s lab investigates how cancer cells can “educate” the immune system—especially NK cells—to support metastasis instead of stopping it.
pubmed.ncbi.nlm.nih.gov/38614094/

Countdown to #MRS2026! We’re excited to share that Dr. Isaac Chan (UT Southwestern) @ithinkichan.bsky.social will be a featured speaker at the Biennial Congress in Salt Lake City!

Membership Levels | Metastasis Research Membership expires after 1 Year.

Meeting registration opens soon. Want to save on registration costs? Become an MRS member!

👉 metastasis-research.org/membership-a...

🔬 Dr. Pepper Schedin (OHSU) studies how normal breast development shapes cancer risk and outcomes, with a focus on pregnancy‑ and menopause‑associated biology.
www.pnas.org/doi/abs/10.1...

🔬 Dr. Bora Lim (MD Anderson) is a translational investigator advancing therapeutic strategies for aggressive breast cancer, using tools like liquid biopsy and single‑cell genomics.
pubmed.ncbi.nlm.nih.gov/38838676/